Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe

Elucid

Domain Not Resolving

DNSSEC

Amazon

IPv6

Person Schema

U.S. Server Location

Gravatar Profiles

Amazon Virginia Region

Amazon S3

Amazon Route 53

Blake Richards

Chief Medical Officer

Todd Villines

Will Syring

Vice President of People

Amy Kruglak

Vice President of Quality and Compliance

Doug Shufelt

Principal Image Processing Specialist

Adrian Tsang

Director of Imaging&Algorithms

Shimin Li

Director of Finance

Timothy Heaney

Deep Learning Research Scientist

Akshay Rajeev

Clinical Technologist

Alissa Champigny

Evan Melrose

Kelly Huang

Jason Bottiglieri

President, CEO and Board Director

Scott Burger

Chief Commercial Officer

Andrew J. Buckler

Founder

Joins Elucid

Windi Hary

Senior Vice President, Head of Quality & Regulatory

East Coast Companies With Less Than $10M in Revenue (Top 10K)

Boston Companies With Less Than $500M in Revenue

New England Companies With Less Than $500M in Revenue (Top 10K)

Companies With Less Than $500M in Revenue (Top 10K)

Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

Elevage Medical Technologies

Series C - Elucid

Series B - Elucid

Global Health Impact Fund

MedTex Ventures

Series A - Elucid

Grant - Elucid

Seed Round - Elucid

National Science Foundation

Computer and Software Services and Scientific Services

Boston

Massachusetts

United States

North America

Elucid receives FDA clearance for PlaqueIQ image analysis software

Kelly Huang Takes Charge at Elucid

Elucid Kicks Off Review of its Plaque Analysis Tool

Elucid Names Kelly Huang as CEO

Elucid moves to new Boston HQ

Elucid Moves into New Headquarters in Preparation for Commercial Launch

A non-invasive image analysis software that uses CT angiography and computer algorithms to quantify the extent and stability of arterial plaque.

Software for assessing plaque composition and quantifying plaque to inform heart attack and stroke risk, enabling personalized treatment plans.

Software that restores vessel structure and plaque morphology for complete 3D plaque visibility and analysis, validated with histopathology.

Technology that integrates with CTA scanners, EMR, PACS, and imaging workflows, ensuring secure data transmission.

Combines plaque analysis with FFR for measuring stress-induced ischemia and characterizing plaque risk.

CTA analysis software with additional features for clinical research, evaluating patient outcomes and safety in clinical trials.

Bangladesh

Asia

India

Canada

Poland

Europe

HTML5

Bootstrap

jQuery

Google Analytics

Google Fonts

Wordpress

Vimeo

Google Compute Engine

Gravity Forms

HubSpot Marketing Hub

Elucid is a Boston-based company focused on improving the accuracy, experience, and cost-effectiveness of cardiovascular diagnostic imaging. They leverage machine learning and histologically-validated software to evaluate plaque vulnerability and inform the risk of events such as heart attacks and strokes.

Elucid Bioimaging Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	c155637f
crunchbase profile	general	Nov 25, 2024 12:05 PM	a3d8b0fe
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 1:57 PM	cce31cb3
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ELUCID

Elucid Bioimaging Inc.